Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction

The role of sodium–glucose cotransporter 2 inhibitors (SLTG2i), developed initially as glucose-lowering agents, has represented a novelty in patients with heart failure (HF) and reduced ejection fraction (HFrEF) since dapagliflozin (DAPA-HF study) and empagliflozin (EMPEROR-Reduced study) were able...

Descripción completa

Detalles Bibliográficos
Autores principales: De Lorenzi, Andrea Beatriz, Kaplinsky, Edgardo, Zambrano, Marx Rivera, Chaume, Laia Tomás, Rosas, Joan Monell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828870/
https://www.ncbi.nlm.nih.gov/pubmed/36660013
http://dx.doi.org/10.7573/dic.2022-7-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828870/
https://www.ncbi.nlm.nih.gov/pubmed/36660013
http://dx.doi.org/10.7573/dic.2022-7-1

Ejemplares similares